SCHEMBL4492299

SCHEMBL4492299

CCc1cc(CC(N)c2nnnn2Cc2ccccc2)cc2c(C)n[nH]c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.41
NPSR1 Q6W5P4 3/20 0.41
KDM4E B2RXH2 7/20 0.40
PKM P14618 1/20 0.40
HSD17B10 Q99714 1/20 0.40
LMNA P02545 4/20 0.38
MAPT P10636 3/20 0.38
HPGD P15428 2/20 0.38
TSHR P16473 4/20 0.37
OPRM1 P35372 1/20 0.37
OPRD1 P41143 1/20 0.37
HTT P42858 1/20 0.37
POLB P06746 1/20 0.37
MAPK1 P28482 2/20 0.37
ALOX15 P16050 2/20 0.37
HRH4 Q9H3N8 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
ALOX12 P18054 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4505335 0.91 ALDH1A1 (0.40) ALDH1A1NPSR1KDM4EHSD17B10LMNA
SCHEMBL5766262 0.72 CALCRL (0.58)
SCHEMBL4492297 0.70 MAPT (0.35) ALDH1A1LMNAMAPTHPGDTSHR
SCHEMBL4559377 0.68 ADORA2A (0.32) PKMALOX15
SCHEMBL7314092 0.65 PAX8 (0.48) ALDH1A1NPSR1KDM4ELMNAMAPT
SCHEMBL7314086 0.65 PAX8 (0.48) ALDH1A1NPSR1KDM4ELMNAMAPT
SCHEMBL1414083 0.64 GHSR (0.53) ALDH1A1NPSR1KDM4ELMNAMAPT
SCHEMBL1414080 0.64 GHSR (0.53) ALDH1A1NPSR1KDM4ELMNAMAPT
SCHEMBL4408776 0.64 ALDH1A1 (0.60) ALDH1A1NPSR1KDM4ELMNAMAPT
SCHEMBL6356262 0.63 TSHR (0.47) ALDH1A1NPSR1KDM4EHSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569578-B2 Heterocyclic anti-migraine agents BRISTOL-MEYERS SQUIBB COMPANY (US) 2009-08-04 US claimed
US-20050153959-A1 3-{1-[4-(7-Methyl-1H-indazol-5-yl)-3-pyridin-2-yl-butyryl]-piperidin-4-yl}-3,4-dihydro-1H-quinazolin-2-one; small molecule; non-peptidic; antagonists of calcitonin gene-related peptide receptors (\"CGRP-receptor\"); neurogenic vasodilation and inflammation, cluster headache BRISTOL-MYERS SQUIBB COMPANY 2005-07-14 US claimed
US-7569578-B2 Heterocyclic anti-migraine agents BRISTOL-MEYERS SQUIBB COMPANY (US) 2009-08-04 US disclosed
US-20050153959-A1 3-{1-[4-(7-Methyl-1H-indazol-5-yl)-3-pyridin-2-yl-butyryl]-piperidin-4-yl}-3,4-dihydro-1H-quinazolin-2-one; small molecule; non-peptidic; antagonists of calcitonin gene-related peptide receptors (\"CGRP-receptor\"); neurogenic vasodilation and inflammation, cluster headache BRISTOL-MYERS SQUIBB COMPANY 2005-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153959-A1 3-{1-[4-(7-Methyl-1H-indazol-5-yl)-3-pyridin-2-yl-butyryl]-piperidin-4-yl}-3,4-dihydro-1H-quinazolin-2-one; small molecule; non-peptidic; antagonists of calcitonin gene-related peptide receptors (\"CGRP-receptor\"); neurogenic vasodilation and inflammation, cluster headache CALCRL, CALCA, BDKRB2 ALDH1A1 2853/4885NPSR1 76/4885KDM4E 4175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.